Proteon Therapeutics, Inc. (NASDAQ:PRTO) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 16, 2017, Proteon Therapeutics, Inc. issued a press
release announcing its financial results for the fourth quarter
and year ended December 31, 2016 and changes to its ongoing Phase
3 clinical trial, PATENCY-2. The press release is attached to
this Current Report as Exhibit 99.1 hereto and is incorporated
herein by reference.
Item 7.01. Regulation FD Disclosure.
The information contained in the Companys press release dated
March 16, 2017 is also incorporated by reference into this Item
7.01.
The information in this Current Report on Form 8-K under Items
2.02 and 7.01, including the exhibit attached hereto, shall not
be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, and shall
not be incorporated by reference into any registration statement
or other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 |
Press release dated March 16, 2017 issued by Proteon Therapeutics, Inc. |
About Proteon Therapeutics, Inc. (NASDAQ:PRTO)
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss. Proteon Therapeutics, Inc. (NASDAQ:PRTO) Recent Trading Information
Proteon Therapeutics, Inc. (NASDAQ:PRTO) closed its last trading session down -0.05 at 1.70 with 15,543 shares trading hands.
